HMM304 - Therapeutic Development

Unit details

Note: You are seeing the 2022 view of this unit information. These details may no longer be current. [Go to the current version]
Year:

2022 unit information

Important Update:

Unit delivery will be in line with the most current COVIDSafe health guidelines. We continue to tailor learning experiences for each unit to achieve the best possible mix of online and on-campus activities that successfully blend our approaches to learning, working and research. Please check your unit sites for announcements and updates.

Last updated: 4 March 2022

Enrolment modes:Trimester 2: Burwood (Melbourne), Waurn Ponds (Geelong)
Credit point(s):1
EFTSL value:0.125
Unit Chair:Trimester 2: Craig Smith
Prerequisite:

HMM202 or SLE212

Corequisite:

Nil

Incompatible with:

Nil

Typical study commitment:

Students will on average spend 150 hours over the teaching period undertaking the teaching, learning and assessment activities for this unit.

Scheduled learning activities - campus:

1 x 2 hour live online BbCollaborate Class per week (Weeks 1-11).
1 x 1 hour (equivalent) additional online learning content/activity per week (Weeks 1-11).
1 x 1 hour Live Seminar per week, face-to-face on campus (Weeks 2-11)

Content

This unit describes how therapeutics such as pharmacological drugs are discovered and developed, in order to treat disease. Non-targeted and targeted drug discovery is discussed, in addition to target validation, in the contexts of big pharmaceutical companies and smaller research laboratories. Drug development strategies and pipelines that are adopted by big pharmaceutical companies are then described, including the chemical optimisation of lead compounds, pre-clinical and clinical trials, commercialisation and post-market considerations.

ULO These are the Learning Outcomes (ULO) for this unit. At the completion of this unit, successful students can: Deakin Graduate Learning Outcomes

ULO1

 Explain the principles of drug discovery and development and have a basic understanding of its role in society.

GLO1: Discipline-specific knowledge and capabilities
GLO4: Critical thinking

ULO2

 Be able to complete a critical evaluation of the drug development process, using case study examples.

GLO1: Discipline-specific knowledge and capabilities
GLO2: Communication
GLO3: Digital literacy
GLO5: Problem solving
GLO7: Teamwork

ULO3

 Use digital and non-digital means to search for current and relevant supporting scholarly evidence and make clear and cohesive arguments that are correctly referenced, within the discipline of therapeutic development.

GLO2: Communication
GLO3: Digital literacy

ULO4

 Present information in a clear, accurate and concise manner using various means (e.g., written report) to specialists and non-specialists within the discipline of drug development. GLO2: Communication

Assessment

Trimester 2:
Assessment description Student output Grading and weighting
(% total mark for unit)		 Indicative due week
Assessment 1: Workshop assessments MCQs from 2 workshops 8%
  • Workshop 1: Week 4
  • Workshop 2: Week 10
Assessment 2: Mid-trimester test 45 minutes 17%
  • Week 5
Assessment 3: Poster presentation Poster and verbal description 25%
  • Week 8
Assessment 4: Examination 2 hours 50%
  • Examination period

The assessment due weeks provided may change. The Unit Chair will clarify the exact assessment requirements, including the due date, at the start of the teaching period.

Learning Resource

The texts and reading list for the unit can be found on the University Library via the link below: HMM304 Note: Select the relevant trimester reading list. Please note that a future teaching period's reading list may not be available until a month prior to the start of that teaching period so you may wish to use the relevant trimester's prior year reading list as a guide only.

Unit Fee Information

Click on the fee link below which describes you: